Subscriber access provided by UNIVERSITY OF TOLEDO LIBRARIES
Biochemical and structural studies of the interaction between ARAP1 and CIN85 Qingxia LI, Wanfa YANG, Yue WANG, and WEI LIU Biochemistry, Just Accepted Manuscript • DOI: 10.1021/acs.biochem.8b00057 • Publication Date (Web): 20 Mar 2018 Downloaded from http://pubs.acs.org on March 26, 2018
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
1 2
Biochemical and structural studies of the interaction between ARAP1
3
and CIN85
4
Qingxia Li1, Wanfa Yang2,3, Yue Wang1, Wei Liu1,2*
5 6
1
7
Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center,
8
Shenzhen 518036, China
Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute,
9 10
2
11
of Science and Technology
Division of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University
12 13
3
14
Study, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong
Center of Systems Biology and Human Health, School of Science and Institute for Advanced
15 16
Running title: Biochemical and structural characterization of the ARAP1/CIN85 interaction
17
18
19
*Correspondence address. Tel/Fax: +86-755-83923333-3615; E-mail:
[email protected] 20
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
21
Abstract.
22
Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1
23
(ARAP1), Cbl-interacting protein of 85 kDa (CIN85), and casitas B-lineage lymphoma
24
(Cbl) play important roles in epidermal growth factor receptor (EGFR) internalization
25
and recycling. In previous studies, ARAP1 was found to interact with CIN85, and their
26
interaction attenuated the ubiquitination of EGFR. However, the molecular
27
mechanism was still unclear. In this study, we first biochemically and structurally
28
characterized the interaction between ARAP1 and CIN85, and found that the CIN85
29
SH3B domain bound to the ARAP1 PXPXXRX (except P) XXR/H/K motif with high
30
affinity and specificity. Based on this binding model, we further predicted other
31
potential CIN85 binding partners and tested their interactions biochemically.
32
Moreover, our swapping data and structure alignment analysis suggested that the
33
β2-β3 loops of the CIN85 SH3 domains and the H87ARAP1/E132CIN85 interaction were
34
critical for ARAP1 binding specificity. Finally, our competitive analytical gel-filtration
35
chromatography and isothermal titration calorimetry (ITC) results showed that
36
ARAP1 could compete with Cbl for CIN85 binding, which provides a biochemical basis
37
for the regulatory roles of ARAP1 in the CIN85-mediated EGFR internalizing process.
38
Key words: ARAP1, CIN85, Cbl, SH3 domain, Crystal structure
39 40 41 42
Introduction. The ADP-ribosylation factor GTPase-activating proteins (Arf GAPs) are critical for
ACS Paragon Plus Environment
Page 2 of 24
Page 3 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
43
the dynamic regulation of the actin cytoskeleton and membrane trafficking (1). Arf-
44
GAP with Rho-GAP domain, ANK repeat and PH domain-containing proteins (ARAPs)
45
belong to a special subfamily of Arf GAPs with similar domain organizations, each of
46
which contains a SAM domain, a proline-rich (PR) domain, an Arf GAP domain, a
47
Rho GAP domain, two ankyrin repeats, a Ras-associating domain, and five PH
48
domains (Fig. 1B). The ARAPs have been shown as the point of convergence for Arf
49
and Rho signaling and are involved in cytoskeleton reorganization and Golgi
50
apparatus remodeling (2-7). In addition, as a member of the ARAP family, ARAP1
51
has also been reported to be involved in the endocytic trafficking of membrane
52
receptors such as epidermal growth factor receptor (EGFR) (8, 9) and TNF-related
53
apoptosis-inducing ligand receptor 1 (TRAIL-R1) (10).
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72
Figure 1. Verification of the ARAP1/CIN85 interaction and mapping their minimal interaction regions A. Schematic diagram of the domain organization of CIN85. B. Domain organization of ARAP1. C. Previously identified CIN85 binding region in ARAP1 (aa 1-100) and proline-rich sequences in ARAP1 aa 1-100. D. Sequence alignment of the two matched segments in the ARAP1 1-100 region according to the previously reported binding model. E. A 1:1 stoichiometric mixture of ARAP1 1-100 and Trx-CIN85 SH3ABC proteins (100 µM each) had a significantly smaller elution volume than the individual proteins, indicating that the interaction was quite strong. F. Binding affinity between the ARAP1 1-100 and CIN85 SH3ABC tandem was measured by ITC assay. Kd = 0.86 ± 0.54 μM, N = 1.10 ± 0.02. G. Summary of the dissociation constants derived from the ITC experiments to deduce the minimal interaction region of the CIN85 SH3ABC tandem in the ARAP1 1-100 region. H. A 1:1 stoichiometric mixture of ARAP1 P2 (aa 80-90) and Trx-CIN85 SH3B proteins (100 µM each) had a significant elution volume shift compared to the individual proteins, showing that they strongly interacted with each other.
ACS Paragon Plus Environment
Page 4 of 24
Page 5 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
73 74 75 76 77
I. Binding affinity of the interaction between ARAP1 P2 (aa 80-90) and the CIN85 SH3B domain was measured by ITC. Kd = 0.32 ± 0.03 μM, N = 0.98 ± 0.00. J. Summary of the dissociation constants derived from the ITC experiments to deduce the minimal interaction region of ARAP1 P2 (aa 80-90) in the CIN85 SH3ABC tandem. ND means not detectable.
78
79
EGFR is a member of the erythroblastic leukemia viral oncogene homolog (ErbB)
80
family of receptor tyrosine kinases (RTKs). The spatial and temporal distribution of
81
EGFR is strictly controlled, and the degradation and recycling of EGFR play
82
indispensable roles in this process (11). The Cbl-interacting protein of 85 kDa (CIN85)
83
is an adapter protein that contains three Src homology 3 (SH3) domains, a proline-
84
rich region, and a coiled-coil (Cc) domain (Fig. 1A). It has been reported that CIN85,
85
through its SH3B domain, interacts with the proline-rich region of casitas B-lineage
86
lymphoma (Cbl) (12, 13) and regulates the endocytosis and degradation of EGFR (14-
87
16). Breaking the CIN85/Cbl interaction is sufficient to block EGF receptor
88
internalization, delay receptor degradation, and enhance EGF-induced gene
89
transcription (17).
90
In previous studies, ARAP1 has been reported to regulate the intracellular
91
trafficking of EGFR (8, 9). Down-regulation of ARAP1 promotes the internalization
92
and subsequent degradation of EGFR (8). Using the yeast two-hybrid method, the 1-
93
100 region of ARAP1 has been identified to interact with CIN85 and drive the exit of
94
EGFR from the degradative pathway to the recycling pathway by competing with Cbl
95
for the CIN85 interaction (18). However, the detailed biochemical and structural
96
mechanisms remain unclear.
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
97
In this study, we first biochemically characterized the interaction between
98
ARAP1 and CIN85 using analytical gel-filtration chromatography and isothermal
99
titration calorimetry (ITC). The results showed that ARAP1 aa 80-90 bound to the
100
CIN85 SH3B domain with a 1:1 molar ratio, and their binding affinity was 0.32 ± 0.03
101
μM. Then, X-ray crystallography was used to elucidate the molecular mechanism of
102
this highly specific interaction, and a general binding model of the CIN85 SH3B
103
domain was proposed. Following the binding model, other potential CIN85 binding
104
partners were found, and their interactions with CIN85 were tested biochemically. In
105
addition, the structure also allowed us to illustrate the molecular basis of the ARAP1
106
binding specificities of the CIN85 SH3 domains. Finally, using competitive analytical
107
gel-filtration chromatography and ITC assays, we determined the relationship
108
between the ARAP1, CIN85, and Cbl, which showed that ARAP1 could compete with
109
Cbl for CIN85 binding. This work provides a biochemical basis of the regulatory roles
110
of ARAP1 in the CIN85-mediated EGFR internalizing process.
111 112
Materials and Methods.
113
Protein expression and purification
114
The cDNA sequences encoding different boundaries of mouse ARAP1 (NCBI
115
accession code: NM_001040111.1) and CIN85 (NCBI accession code: NM_021389.6)
116
were PCR-amplified from a mouse cDNA library and cloned into a modified pET32a
117
vector (19, 20). The plasmids encoding the recombinant proteins were transformed
118
into E. coli BL21 (DE3). A single colony was inoculated in LB media containing 50
ACS Paragon Plus Environment
Page 6 of 24
Page 7 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
119
µg/ml ampicillin. When A600 nM = 0.8, the cells were induced with 0.1 mM IPTG at
120
16°C for 20 h. Then the collected cells were homogenized in a high-pressure
121
homogenizer (Union-biotech, Shanghai), and the cell lysate was centrifuged at
122
39,191 g for 30 min at 4°C. The recombinant proteins in the supernatant were
123
purified by Ni2+ Sepharose™ 6 Fast Flow beads (GE Healthcare, USA), followed by a
124
Superdex-200 prep grade size-exclusion (GE Healthcare) column in buffer of 50 mM
125
Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT. The ARAP1 aa 80-90 peptide
126
was commercially synthesized by ChinaPeptides Co., Ltd.
127 128
Analytical gel-filtration chromatography assay
129
Analytical gel-filtration chromatography assays were carried out on an ÄKTA
130
purifier system using a Superose 12 10/300 GL column (GE Healthcare). Protein
131
samples (50 µM each, 100 µL) were injected into the column equilibrated with buffer
132
of 50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT.
133 134
Isothermal titration calorimetry (ITC) assay
135
ITC assays were carried out on a MicroCal ITC-200 calorimeter (Malvern, USA) at
136
25°C in buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT. The
137
protein concentrations in the syringe and the cell were around 200 μM and 20 μM,
138
respectively. The titration data were analyzed using the Origin 8.0 program and fitted
139
by a one-site binding model.
140
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
141
Crystallography
142
Crystals of the ARAP1 P2/CIN85 SH3B complex (in 50 mM Tris-HCl pH 7.5, 100
143
mM NaCl, 1 mM EDTA, 1 mM DTT buffer) were obtained by the sitting drop vapor
144
diffusion method at 16°C. The crystals were grown in buffer containing 0.2 M sodium
145
acetate trihydrate, 0.1 M Tris hydrochloride pH 8.5, and 30% w/v polyethylene glycol
146
4000. X-ray diffraction data were collected at the Shanghai Synchrotron Radiation
147
Facility BL19U1 at 100K. Diffraction data were processed and scaled using HKL3000
148
(21).
149
The structure of the ARAP1 P2/CIN85 SH3B complex was solved by molecular
150
replacement with the model of the second SH3 domain of CD2AP (PDB: 3U23) using
151
PHASER (22). Further manual model building and refinement were completed
152
iteratively using Coot (23) and PHENIX (24). The final model was validated by
153
MolProbity (25). The final statistics of X-ray crystallographic data collection and
154
model refinement are summarized in Table 1. All structure figures were prepared by
155
PyMOL. The structure factors and the coordinates of the structure reported in this
156
work have been deposited to Protein Data Bank (PDB) under the accession code:
157
5XHZ.
158
Table. 1 Statistics of X-ray crystallographic data collection and model refinement. Data Collection Datasets Space group Wavelength (Å) Unit cell parameters (Å) Resolution range (Å) No. of unique reflections Redundancy I/σ Completeness (%)
ARAP1_80-90/CIN85_SH3B P 43 0.9785 a=b=66.162, c=34.935 α=β=γ=90° 50-1.32 (1.34-1.32) 34450 (1749) 9.3 (8.7) 19.6 (2.0) 96.0 (97.4)
ACS Paragon Plus Environment
Page 8 of 24
Page 9 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
Rmergea (%) Structure Refinement Resolution (Å) Rcrystb /Rfreec (%) Rmsd bonds (Å)/angles (°) Average B factor(Å2)d No. of atoms Protein atoms Other molecules No. of reflections Working set Test set Ramachandran plot regions d Favored (%) Allowed (%) Outliers (%) 159 160 161 162 163 164 165 166 167
8.1 (69.8) 50-1.32 16.3/18.7 0.005/0.811 18.73 1219 269 34440 1766 98.50 1.50 0
Numbers in parentheses represent the value for the highest-resolution shell. Rmsd, root-mean-square deviation. a. Rmerge = Σ |Ii - | / ΣIi, where Ii is the intensity of measured reflection and is the mean intensity of all symmetry-related reflections. b. Rcryst =Σ||Fcalc| – |Fobs||/ΣFobs, where Fobs and Fcalc are observed and calculated structure factors. c. Rfree =ΣT||Fcalc| – |Fobs||/ΣFobs, where T is a test dataset of about 5% of the total unique reflections randomly chosen and set aside prior to refinement. d. B factors and Ramachandran plot statistics were calculated using MolProbity (25).
168 169
Results and Discussion.
170
ARAP1 aa 80-90 (P2) specifically bound to CIN85 SH3B with a 1:1 ratio
171
Previously, the ARAP1 1-100 region was identified to interact with CIN85 in a
172
yeast two-hybrid screen (18). We first verified the interaction by using purified
173
ARAP1 1-100 and CIN85 1-333 (named as SH3ABC tandem) proteins. On an analytical
174
gel-filtration column, a 1:1 mixture of ARAP1 1-100 and CIN85 SH3ABC tandem was
175
eluted at a volume clearly smaller than each of the two individual proteins alone (Fig.
176
1E), suggesting that the two proteins formed a stable complex. Then, ITC assays were
177
used to quantify the interaction, and the result showed that the two proteins bound
178
to each other with a 1:1 stoichiometry and the dissociation constant (Kd) was 0.86 ±
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
179
0.54 μM (Fig. 1F).
180
It has also been shown that the ARAP1 PXPXXRXXXR motif specifically binds to
181
CIN85 SH3 domains (18). However, in the ARAP1 1-100 region, we found two
182
matched segments (i.e. aa 70-80 and aa 80-90) (Fig. 1C and D). So we divided the
183
ARAP1 1-100 region into four parts (SAM domain, P1 (aa 70-80), P2 (aa 80-90), aa 90-
184
100) and tested their interactions with CIN85 SH3 domains, respectively (Fig. 1C). As
185
a result, the SAM domain, P1, and aa 90-100 did not interact with the CIN85 SH3ABC
186
tandem in either analytical gel-filtration chromatography or ITC assays (Fig. 1G and
187
S1A1, A2, B1, B2, D1, and D2), while P2 bound to the CIN85 SH3ABC tandem in both
188
the analytical gel-filtration chromatography and ITC assays, and their binding affinity
189
was measured to be 1.10 ± 0.6 μΜ (Fig. 1G and Fig. S1C1, C2).
190
In the next step, we examined which SH3 domain of CIN85 was responsible for
191
binding to ARAP1 P2. In analytical gel-filtration chromatography and ITC experiments,
192
CIN85 SH3AB tandem and SH3BC tandem showed strong binding to ARAP1 P2,
193
indicating that their mutual part, the SH3B domain, might be the binding site of
194
ARAP1 P2 (Fig. S2A1, A2, B1, and B2). To confirm this hypothesis, we further purified
195
the isolated SH3 domains of the CIN85 SH3ABC tandem (namely SH3A, aa 1-77; SH3B,
196
aa 96-160; and SH3C, aa 257-333). Interestingly, the P2 bound to both the SH3B
197
domain and the SH3C domain with binding affinities of 0.32 ± 0.03 μM and 6.41 ±
198
0.42 μM, respectively (Fig. 1H, I, J; and Fig. S2D1, D2). These results were
199
contradictory to the 1:1 binding ratio in the previous ITC titration result (Fig. 1F). We
200
then speculated that the linker region outside the SH3B and SH3C domains might
ACS Paragon Plus Environment
Page 10 of 24
Page 11 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
201
also contribute to the binding. So we extended the boundary of the SH3C domain to
202
linker2-SH3C (aa 161-333) (Fig. 1J and Fig. S2E1, E2) and the SH3B domain to linker1-
203
SH3B-linker2 (aa 69-256) (Fig. 1J and Fig. S2F1, F2), respectively. In line with our
204
expectations, we did not detect an interaction between ARAP1 P2 and linker2-SH3C,
205
indicating that the SH3C domain was autoinhibited by linker2 (Fig. 1J and Fig. S2E1,
206
E2). In contrast, linker1-SH3B-linker2 still bound to ARAP1 P2 with a similar strong
207
binding affinity (0.32 ± 0.02 μΜ) (Fig. 1J and Fig. S2F1, F2), confirming that the SH3B
208
domain was the binding site of ARAP1 P2.
209 210 211
The crystal structure of the ARAP1 P2/CIN85 SH3B complex revealed the molecular basis of the binding specificity
212
To understand the molecular basis of the ARAP1/CIN85 interaction, we solved
213
the crystal structure of the ARAP1 P2/CIN85 SH3B protein complex at 1.32 Å
214
resolution (Table 1). The overall structure showed that CIN85 SH3B is composed of
215
four β-strands (β1-4) (Fig. 2A). Detailed structural analysis revealed that the PVP
216
motif of the ARAP1 P2 peptide was inserted into the hydrophobic surface formed by
217
F107, Y109, W135, P148, and F151 of the CIN85 SH3B domain (Fig. 2B). The side
218
chains of the R86, H87, and R90 of ARAP1 formed charge-charge interactions with
219
D115, E132, and E137 of CIN85, respectively. And the backbone amide hydrogen of
220
H87ARAP1 and the side chain of E132CIN85 also formed a hydrogen-bond (Fig. 2C).
221
Mutations of these critical amino acids greatly weakened the binding of ARAP1 P2 to
222
CIN85 SH3B (Fig. 2D).
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
223 224 225 226 227 228 229 230 231 232 233 234 235 236
Figure 2. Overall structure of the ARAP1 P2 (80-90)/CIN85 SH3B complex and the detailed interaction interface A. Ribbon diagram of the ARAP1 P2 (80-90)/CIN85 SH3B domain complex structure. The ARAP1 P2 (aa 80-90) and CIN85 SH3B domains are colored in magenta and green, respectively. B. Surface representation the CIN85 SH3B domain. The positively charged amino acids of the CIN85 SH3B domain are colored in blue, the negatively charged residues in red, the hydrophobic residues in yellow, and the others in white. The ARAP1 P2 (aa 80-90) peptide is displayed in a stick model and colored in magenta. The PVP motif of P2 is highlighted by the red circle. C. The residues involved in the critical charge-charge and hydrogen bonding interactions are shown in the stick model and their interactions are highlighted by red dashed lines. D. Summary of the ITC results showing that mutations of the critical residues in the interface weakened the binding. H87A, R90H, and R90K mutations did not significantly change the binding affinity. ND means not detectable.
237
Since the P1 segment (PVPLPRPAPR) also fitted with the previously reported
238
CIN85 SH3 domain binding model (PXPXXRXXXR) (18) (Fig. 1D), we were curious as to
239
why it could not bind to the SH3B domain. We found that by forming a hydrogen
240
bond with E132CIN85, the backbone hydrogen of H87ARAP1 played a vital role in
ACS Paragon Plus Environment
Page 12 of 24
Page 13 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
241
interacting with the CIN85 SH3B domain. The H87P mutation, which lacks the
242
backbone amide hydrogen, greatly decreased the ARAP1 P2/CIN85 SH3B interaction
243
(Fig. 2D). Consistently, the counterpart of H87 in P1 is P77 (Fig. 1D), which perfectly
244
explains why P1 could not interact with the CIN85 SH3B domain. In addition, we also
245
predicted that any other amino acid except P at this position would be favorable to
246
provide the backbone hydrogen to interact with E132CIN85. Consistent with our
247
prediction, the H87A mutation showed a slightly weakened binding affinity compared
248
to wild type P2, since it lost the charge-charge interaction between the side chains of
249
H87ARAP1 and E132CIN85 (Fig. 2D). In addition, we proposed that ARAP1 R90 could also
250
be replaced by H or K, which could still form charge-charge interactions or hydrogen
251
bonding with E137 of CIN85. Our resulting R90H and R90K mutation data strongly
252
supported this prediction (Fig. 2D). Therefore, according to our structural information
253
and mutagenesis data, we generalized the binding motif of the CIN85 SH3B domain
254
to be: PXPXXRX (except P) XXR/H/K.
255
In the next step, we searched for more potential CIN85 interacting proteins
256
based on our structure. Since H87 can provide hydrogen bonding and charge-charge
257
interactions simultaneously, in order to find strong binders of the CIN85 SH3B
258
domain, we used PXPXXRHXXR/H/K as the template to search the human protein
259
sequence
260
(https://prosite.expasy.org/scanprosite/). Five more potential CIN85 binding partners
261
were found. Using the purified proteins and ITC experiments, we biochemically
262
verified their interactions with the CIN85 SH3B domain (Table 2). Among them, a
database
using
the
ACS Paragon Plus Environment
ScanProsite
tool
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 24
263
downstream scaffold protein of EGF signaling, named Kinase suppressor of Ras 2
264
(KSR2), bound to the CIN85 SH3B domain with a strong binding affinity of 1.74 ± 0.16
265
μΜ. A previous simulation study has shown that KSR and CIN85 can collaborate with
266
other proteins to fine-tune the sensitivity of EGFR endocytosis and ERK activation
267
(26). So it is very likely that KSR is another binding partner of CIN85.
268 269
Table 2. Prediction of the potential binding partners of the CIN85 SH3B domain. Name ARAP1_80-90 WT KSR_250-259 HCFC1_28-37 MRC2_8-17 PLD1_140-149 DNN_360-369
270 271 272
Sequence PVPMKRH MKRHIF RHIFR IFR PSPRQRH RQRHAV RHAVR AVR PVPRPRH RPRHGH RHGHR GHR PAPWPRH WPRHLL RHLLR LLR PIPTRRH TRRHTF RHTFR TFR PAPRSRH RSRHHL RHHLK HLK
Kd (μM) 0.32±0.03 1.74±0.16 3.00±0.28 11.16±1.07 24.01±4.10 41.67±3.56
We predicted five proteins that contain a PXPXXRHXXR/H/K (highlight in yellow) motif by using the ScanProsite tool. The binding affinities between the predicted proteins and the CIN85 SH3B domain were measured by ITC.
273 274
ARAP1 binding specificities of the three SH3 domains in CIN85
275
Both the sequence and overall structure alignment showed that CIN85 SH3A,
276
SH3B, and SH3C domains were highly similar (Fig. 3A and B). The three key charged
277
residues (D115, E132, E137) which bound to ARAP1 P2 were also conserved in the
278
SH3A, SH3B, and SH3C domains (red boxes in Fig. 3A). However, ARAP1 P2 only
279
interacted with the isolated CIN85 SH3B and SH3C domains instead of the SH3A
280
domain. We therefore examined the structural basis of their binding specificities.
ACS Paragon Plus Environment
Page 15 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301
Figure 3. Structural basis of the CIN85 SH3 domain binding specificity A. Sequence alignment of human and mouse CIN85 SH3A, SH3B, and SH3C domains. Key residues involved in ARAP1 binding are highlighted in the red boxes. The β2-β3 linker regions are labeled with the blue box. Secondary structure diagrams of the CIN85 SH3A, SH3B, and SH3C domains derived from the ARAP1 P2 (aa 80-90)/CIN85 SH3B complex structure and the PDB database (SH3A: 2BZ8 (27), SH3C: 2YDL (28)) are shown above the sequence alignment and colored in purple, green, and orange, respectively. B. Structure alignment of the three SH3 domains of CIN85. The ARAP1 P2 (aa 80-90) peptide is colored in magenta and the CIN85 SH3A (PDB ID: 2BZ8 (27)), SH3B (PDB ID: 5XHZ), and SH3C (PDB ID: 2YDL (28)) domains are colored in purple, green, and orange, respectively. The β2-β3 linker regions are enlarged in the black box. The charge-charge and hydrogen bonding interactions between H87ARAP1 and E132SH3B are displayed by the red dashed lines. C. Summary of the binding affinities between ARAP1 P2 (aa 80-90) and the wild-type SH3B domain or chimeric CIN85 SH3 domains. “SH3A with B linker” means that the β2-β3 linker of the SH3A domain was replaced by that of the SH3B domain. Other chimeras followed this rule. D. Structure alignment of the CIN85 SH3B domain and SH3A domain (PDB ID: 2BZ8 (27)). The critical amino acids in the charge-charge and hydrogen bonding interaction interface are aligned and shown in D1, D2, and D3. The critical charge-charge and hydrogen bonding interactions between CIN85 SH3B and the ARAP1 P2 (aa 80-90) peptide are displayed by red dashed lines. E. Structure alignment of CIN85 SH3B and SH3C domain (PDB ID: 2YDL (28)). The critical amino
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
302 303 304
acids in the charge-charge and hydrogen bonding interaction interface are aligned and shown in E1, E2, and E3. The critical charge-charge and hydrogen bonding interactions between CIN85 SH3B and the ARAP1 P2 (aa 80-90) peptide are displayed by red dashed lines.
305
By carefully analyzing the sequence alignment, we found that the β2-β3 loop
306
was the most variable region between the three SH3 domains of CIN85 (blue box in
307
Fig. 3A and enlarged region in Fig. 3B). To test our hypothesis, we created chimeric
308
SH3 domains by swapping the β2-β3 loops between SH3B and SH3A/SH3C domains.
309
ITC results showed that the SH3A domain and the SH3C domain carrying the β2-β3
310
loop from the SH3B domain had significantly enhanced binding affinities to ARAP1
311
(Fig. 3C). In contrast, weakened interactions were detected between ARAP1 and the
312
SH3B domain carrying the β2-β3 loop either from the SH3A or SH3C domains (Fig.
313
3C).
314
In addition, in the structure alignment, we found that E38SH3A, D16 SH3A, and
315
D308SH3C, D284SH3C showed similar orientations compared to E137SH3B, D115SH3B (Fig.
316
3D1, D2, E1, and E2). However, the orientation of D33SH3A (the counterpart of
317
E132SH3B in the β2-β3 loop) was not favorable for its interaction with H87ARAP1 (Fig.
318
3D3). In contrast to D33SH3A, D303SH3C showed only a slightly different orientation
319
from E132SH3B (Fig. 3E3). Thus, the structure alignment provided cues as to why the
320
SH3A domain could not bind to ARAP1, and why the isolated CIN85 SH3C domain
321
could still bind to ARAP1 P2 with moderate affinity (6.47 ± 0.42 μΜ) (Fig. S2D2).
322
Taken together, our swapping data and structural alignment suggested that the
323
β2-β3 loops and the H87ARAP1/E132CIN85 interaction play important roles in the ARAP1
324
binding specificities of the three SH3 domains in CIN85.
325
ACS Paragon Plus Environment
Page 16 of 24
Page 17 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
326
ARAP1 competed with Cbl for association with the CIN85 SH3B domain
327
Previously, aa 825-835 (PERPPKPFPRR) of Cbl was reported to bind to the CIN85
328
SH3B domain (13). We confirmed their binding by analytical gel-filtration
329
chromatography and ITC experiments (Kd = 16.26 ± 2.08 μM) (Fig. 4A and C). Then we
330
performed competition assays to test the relationship between ARAP1, CIN85, and
331
Cbl. Analytical gel-filtration chromatography data showed that by adding excessive
332
ARAP1 P2 peptide (molar ratio = 1.2:1) into the protein mixture, the Trx-Cbl peptide
333
did not form a complex with the CIN85 SH3B domain anymore (Fig. 4B). Consistently,
334
the ITC results showed that Trx-Cbl did not interact with a protein mixture of Trx-
335
ARAP1 P2 (aa 80-90) and the CIN85 SH3B domain (molar ratio = 1.2:1) (Fig. 4D). In
336
contrast, Trx-ARAP1 P2 (aa 80-90) strongly interacted with a protein mixture of Trx-
337
Cbl and the CIN85 SH3B domain (molar ratio = 1.2:1) (Fig. 4E), and the dissociation
338
constant (Kd = 0.29 ± 0.04 μM) was similar to that of the ARAP1 P2/CIN85 SH3B
339
interaction. Therefore, our results showed that the CIN85 SH3B domain preferred to
340
bind to Trx-ARAP1 P2 instead of the Trx-Cbl peptide, which provides direct
341
biochemical evidence that the presence of ARAP1 P2 breaks the complex formation
342
between Cbl and the CIN85 SH3B domain.
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
343 344 345 346 347 348 349 350 351 352 353 354 355 356 357
Figure 4. ARAP1 P2 (aa 80-90) peptide competes with Cbl to interact with the CIN85 SH3B domain A. A 1:1 stoichiometric mixture of Trx-Cbl peptide (PERPPKPFPRR) and CIN85 SH3B domain (100 µM each) had a significantly smaller elution volume than the individual proteins, indicating that they interacted with each other in the analytical gel-filtration column. B. Competitive analytical gel-filtration experiments showed that by pre-mixing with slightly excessive (120 µM) synthetic ARAP1 P2 (aa 80-90) peptide (RPVPMKRHIFR), the Trx-CIN85 SH3B domain (100 µM) did not interact with the Trx-Cbl peptide (100 µM). C. ITC assay was used to measure the binding affinity between Trx-Cbl and the CIN85 SH3B domain. Kd = 16.26 ± 2.0 2μM. D. In ITC experiments, Trx-Cbl did not interact with the protein mixture of Trx-ARAP1 P2 (aa 80-90) and the CIN85 SH3B domain (molar ratio = 1.2:1). ND means not detectable. E. In ITC experiments, Trx-ARAP1 P2 (aa 80-90) interacted with the protein mixture of Trx-Cbl and the CIN85 SH3B domain (molar ratio = 1.2:1). Kd = 0.29 ± 0.04 μM.
358 359
Conclusions
360
Previously, the ARAP1 1-100 region was found to interact with the CIN85 SH3
361
domains, and a “PXPXXRXXXR” binding model was provided (18). Based on this
ACS Paragon Plus Environment
Page 18 of 24
Page 19 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
362
model, both the ARAP1 70-80 and 80-90 regions can be predicted to bind to CIN85.
363
However, in our study, we only found 1:1 binding between ARAP1 1-100 and CIN85
364
SH3ABC. By re-mapping the binding boundary and solving the high-resolution crystal
365
structure, we elucidated the molecular basis of the ARAP1/CIN85 interaction and
366
generalized a new motif for the strong binding to the CIN85 SH3B domain: PXPXXRX
367
(except P) XXR/H/K. This new binding model explains well why ARAP1 70-80 could
368
not bind to the CIN85 SH3B domain and elucidates the molecular mechanism of the
369
highly specific interaction between the ARAP1 aa 80-90 and CIN85 SH3B domains. In
370
addition, by using this model, we found five more potential binding partners of
371
CIN85 (Table 2). Currently, we have biochemically verified their interactions with the
372
CIN85 SH3B domain. Further investigations are needed to explore the biological
373
importance of these predicted interactions.
374
The three SH3 domains of CIN85 are highly similar in protein sequence and
375
overall structure. However, only the SH3B domain of CIN85 could interact with
376
ARAP1 aa 80-90. By performing swapping studies and structural alignment analysis,
377
we found that the β2-β3 loops and the H87ARAP1/E132CIN85 interaction played
378
important roles in the ARAP1 binding specificities of the three SH3 domains in CIN85.
379
Accidentally, when mapping the minimal ARAP1 P2 binding region in the CIN85
380
SH3ABC tandem, we found that P2 could bind to the isolated SH3C domain (aa 257-
381
333) but not with the longer version (linker2-SH3C, aa 161-333). This finding
382
indicated that the SH3C domain might be auto-inhibited by the long linker between
383
the SH3B and SH3C domains (Fig. 1A). The molecular mechanism of this auto-
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
384
inhibition will be an interesting subject for further exploration.
385
Cbl, CIN85, and ARAP1 play important roles in the endosomal sorting and
386
degradation of EGFR (13, 14, 17, 27, 29). In this study, we biochemically explored the
387
relationship between ARAP1, CIN85, and Cbl. Competitive experimental results
388
showed that ARAP1 aa 80-90 peptide could break down the interaction between Cbl
389
and CIN85. In future work, we will test whether adding the ARAP1 aa 80-90 peptide
390
can significantly affect the surface expression levels of EGFR in EGFR high-expressing
391
cancer cells and animal models.
392 393 394 395
Accession Numbers The structure factors and coordinates of the CIN85 SH3B/ARAP1 80-90 structure have been deposited in the PDB under the accession code PDB: 5XHZ.
396 397
Supplementary Materials
398
The supplementary materials include three figures. Figure S1 and S2 support the
399
results of Fig 1G and J, showing the detailed analytical gel-filtration chromatography
400
and ITC results for mapping the shortest CIN85 SH3ABC tandem binding region in
401
ARAP1, and the shortest ARAP1 P2 binding region in the CIN85 SH3ABC tandem.
402
Figure S3 shows the control experiments of Figure 4.
403 404 405
Acknowledgments We thank the Shanghai Synchrotron Radiation Facility (SSRF) BL19U1 for X-ray
ACS Paragon Plus Environment
Page 20 of 24
Page 21 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
406
beam times. This work was supported by the National Natural Science Foundation of
407
China (No.31400647 and 31670765), the National Basic Research Program of China
408
(973 Program) (2014CB910204), the National Key Research and Development
409
Program (2016YFA0501900), the Natural Science Foundation of Guangdong Province
410
(2016A030312016), and Shenzhen Basic Research Grants (JCYJ20160229153100269,
411
JCYJ20160427185712266 and JCYJ20170411090807530).
412
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
413
For Table of Contents Use Only.
414 415
Biochemical and structural studies of the interaction between ARAP1
416
and CIN85
417
Qingxia Li1, Wanfa Yang2,3, Yue Wang1, Wei Liu1,2*
418 419 420 421
ACS Paragon Plus Environment
Page 22 of 24
Page 23 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Biochemistry
422 423 424 425 426 427
References:
428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464
1
Randazzo PA, Hirsch DS. Arf GAPs: multifunctional proteins that regulate membrane traffic and
actin remodelling. CELL SIGNAL 2004, 16: 401-413 2
I ST, Nie Z, Stewart A, Najdovska M, Hall NE, He H, Randazzo PA, et al.. ARAP3 is transiently
tyrosine phosphorylated in cells attaching to fibronectin and inhibits cell spreading in a RhoGAPdependent manner. J CELL SCI 2004, 117: 6071-6084 3
Miura K, Jacques KM, Stauffer S, Kubosaki A, Zhu K, Hirsch DS, Resau J, et al.. ARAP1: a
point of convergence for Arf and Rho signaling. MOL CELL 2002, 9: 109-119 4
Krugmann S, Anderson KE, Ridley SH, Risso N, McGregor A, Coadwell J, Davidson K, et al..
Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. MOL CELL 2002, 9: 95-108 5
Chen PW, Jian X, Yoon HY, Randazzo PA. ARAP2 signals through Arf6 and Rac1 to control
focal adhesion morphology. J BIOL CHEM 2013, 288: 5849-5860 6
Hasegawa J, Tsujita K, Takenawa T, Itoh T. ARAP1 regulates the ring size of circular dorsal
ruffles through Arf1 and Arf5. MOL BIOL CELL 2012, 23: 2481-2489 7
Yoon HY, Miura K, Cuthbert EJ, Davis KK, Ahvazi B, Casanova JE, Randazzo PA. ARAP2
effects on the actin cytoskeleton are dependent on Arf6-specific GTPase-activating-protein activity and binding to RhoA-GTP. J CELL SCI 2006, 119: 4650-4666 8
Yoon H, Lee J, Randazzo PA. ARAP1 Regulates Endocytosis of EGFR. TRAFFIC 2008, 9: 2236-
2252 9
Daniele T, Di Tullio G, Santoro M, Turacchio G, De Matteis MA. ARAP1 regulates EGF receptor
trafficking and signalling. TRAFFIC 2008, 9: 2221-2235 10
Simova S, Klima M, Cermak L, Sourkova V, Andera L. Arf and Rho GAP adapter protein
ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. APOPTOSIS 2008, 13: 423-436 11
Miaczynska M. Effects of membrane trafficking on signaling by receptor tyrosine kinases. Cold
Spring Harb Perspect Biol 2013, 5: a9035 12
Haglund K, Schmidt MH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface
to inhibit epidermal growth factor receptor downregulation. EMBO REP 2005, 6: 635-641 13
Kowanetz K, Szymkiewicz I, Haglund K, Kowanetz M, Husnjak K, Taylor JD, Soubeyran P, et
al.. Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors. J BIOL CHEM 2003, 278: 39735-39746 14
Ronning SB, Pedersen NM, Madshus IH, Stang E. CIN85 regulates ubiquitination and
degradative endosomal sorting of the EGF receptor. EXP CELL RES 2011, 317: 1804-1816 15
Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, Kajigaya S. Cloning and characterization of a
novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun 2000, 268: 321-328
ACS Paragon Plus Environment
Biochemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497
16
Dikic I. CIN85/CMS family of adaptor molecules. FEBS LETT 2002, 529: 110-115
17
Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin
complex mediates ligand-induced downregulation of EGF receptors. NATURE 2002, 416: 183-187 18
Yoon HY, Kales SC, Luo R, Lipkowitz S, Randazzo PA. ARAP1 association with CIN85 affects
epidermal growth factor receptor endocytic trafficking. BIOL CELL 2011, 103: 171-184 19
Liu W, Wen W, Wei Z, Yu J, Ye F, Liu CH, Hardie RC, et al.. The INAD scaffold is a dynamic,
redox-regulated modulator of signaling in the Drosophila eye. CELL 2011, 145: 1088-1101 20
Wang Y, Li Q, Zheng Y, Li G, Liu W. Systematic biochemical characterization of the SAM
domains in Eph receptor family from Mus Musculus. Biochem Biophys Res Commun 2016, 473: 1281-1287 21
Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol 1997, 276: 307-326 22
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser
crystallographic software. J APPL CRYSTALLOGR 2007, 40: 658-674 23
Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta
Crystallogr D Biol Crystallogr 2010, 66: 486-501 24
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, et al.. PHENIX:
a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66: 213-221 25
Chen VB, Arendall WR, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, et al..
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010, 66: 12-21 26
Huang L, Pan CQ, Li B, Tucker-Kellogg L, Tidor B, Chen Y, Low BC. Simulating EGFR-ERK
signaling control by scaffold proteins KSR and MP1 reveals differential ligand-sensitivity co-regulated by Cbl-CIN85 and endophilin. PLOS ONE 2011, 6: e22933 27
Jozic D, Cárdenes N, Deribe YL, Moncalián G, Hoeller D, Groemping Y, Dikic I, et al.. Cbl
promotes clustering of endocytic adaptor proteins. NAT STRUCT MOL BIOL 2005, 12: 972-979 28
Ortega, R. J., Casares, S., Ringkjobing, J. M., Cardenes, N., Bravo, J., Blackledge, M., Azuaga, A.
I., and van Nuland, N. A. (2013) Distinct ubiquitin binding modes exhibited by SH3 domains: molecular determinants and functional implications, PLOS ONE 8, e73018. 29
Haglund K, Shimokawa N, Szymkiewicz I, Dikic I. Cbl-directed monoubiquitination of CIN85 is
involved in regulation of ligand-induced degradation of EGF receptors. Proc Natl Acad Sci U S A 2002, 99: 12191-12196
498 499 500
ACS Paragon Plus Environment
Page 24 of 24